CRVS · Corvus Pharmaceuticals, Inc.
$13.04
-0.27 (-2.03%)
At close · Jul 29
Market Cap
$1.12B
Shares
84.09M
Corvus Pharmaceuticals, Inc. Earnings Call Transcripts
Every quarterly earnings call for Corvus Pharmaceuticals, Inc. (CRVS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Conference
Investor event
2026-06-08
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-14
Corvus Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Confident tone
ITK mechanism and Treg induction
Phase 2 atopic dermatitis design and timing
Cash runway and financing need
Diluted EPS
$-0.15
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Corvus Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Confident tone
Soquelitinib clinical efficacy in atopic dermatitis
Phase II atopic dermatitis trial
Pipeline expansion to other inflammatory diseases
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q4
2026-01-20
Soquelitinib Cohort 4 Results Webcast
Confident tone
Soquelitinib clinical efficacy in atopic dermatitis
Phase II atopic dermatitis trial
Pipeline expansion to other inflammatory diseases
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Corvus Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Confident tone
Soquelitinib atopic dermatitis program
Phase II atopic dermatitis trial design
Peripheral T cell lymphoma (PTCL) Phase III
Diluted EPS
$-0.12
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Corvus Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Confident tone
Soquelitinib in atopic dermatitis
Phase I Cohort 3 efficacy and safety
China partnership with Angel Pharmaceuticals
Diluted EPS
$-0.10
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Corvus Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Confident tone
Soquelitinib atopic dermatitis Phase 1 efficacy
Phase 2 atopic dermatitis trial planning
Dose selection and pharmacokinetics
Diluted EPS
$-0.13
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-25
Corvus Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone
Socalitinib in atopic dermatitis
Socalitinib in T-cell lymphoma (PTCL)
ALPS (NIH trial)
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Corvus Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Positive tone
Soquelitinib in atopic dermatitis (Phase I)
December data readout / upcoming catalysts
ITK mechanism and Treg/Th17 biology
Diluted EPS
$-0.60
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Corvus Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Diluted EPS
$-0.07
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Corvus Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Confident tone
Soquelitinib Phase III in PTCL
Soquelitinib in Atopic Dermatitis
Ciforadenant in Renal Cell Cancer
Diluted EPS
$-0.12
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-19
Corvus Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Confident tone
Soquelitinib registrational Phase 3 trial in relapsed PTCL
Phase 1 trial of soquelitinib in atopic dermatitis
Business development and partnering
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Corvus Pharmaceuticals, Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-0.12
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Corvus Pharmaceuticals, Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-0.14
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Corvus Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.17
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-28
Corvus Pharmaceuticals, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Corvus Pharmaceuticals, Inc. Q3 FY2022 Earnings Call
Diluted EPS
$-0.32
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Corvus Pharmaceuticals, Inc. Q2 FY2022 Earnings Call
Diluted EPS
$-0.18
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Corvus Pharmaceuticals, Inc. Q1 FY2022 Earnings Call
Diluted EPS
$-0.18
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Corvus Pharmaceuticals, Inc. Q4 FY2021 Earnings Call
Diluted EPS
$-0.20
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q2
2021-07-15
Corvus Pharmaceuticals, Inc. Q2 FY2021 Earnings Call
Diluted EPS
$-0.28
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Corvus Pharmaceuticals, Inc. Q2 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Corvus Pharmaceuticals, Inc. Q1 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-05
Corvus Pharmaceuticals, Inc. Q4 FY2019 Earnings Call
Diluted EPS
$0.92
Audio
Transcript
Slides
8-K10-K
Showing 1–25 of 25 earnings calls
Key facts
CIK
1626971
CUSIP
221015100
13F (30d)
24 filings
24 filers
Visit website
Investor relations